Drug intelligence / Profile preview

KSHN001034

Development stage: Phase 1
Lead developer: Kashiv BioSciences
Modality: Small Molecules
Administration: Intramuscular, Subcutaneous

Overview

KSHN001034 is a **small molecule drug** under development as an **intramuscular or subcutaneous prodrug of fulvestrant**, designed to act as an **estrogen receptor antagonist** (specifically, a selective estrogen receptor degrader, or SERD). Its mechanism of action mirrors fulvestrant, binding to and promoting degradation of the estrogen receptor, thereby blocking estrogen signaling. KSHN001034 is being evaluated for its safety, tolerability, and pharmacokinetic equivalence to Faslodex (fulvestrant) in healthy postmenopausal women, with the goal of offering a potentially improved or alternative formulation for hormone receptor-positive breast cancer therapy[1][3][7][8][10].

Other names: fulvestrant biosimilarKashiv fulvestrant

Targets

ESR2 (ERβ)ESR1 (ERα)

Beyond the preview

Go deeper on KSHN001034.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KSHN001034.

Explore the full profile